| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 4. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | beclometasone dipropionate/formoterol fumarate dihydrate (Fostair pMDI®) |
| Formulation | 200 mcg/6 mcg inhalation powder |
| Reference number | 2924 |
| Indication | In adults for the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist; or patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists |
| Company | Chiesi Ltd |
| BNF chapter | Respiratory system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 06/10/2015 |